Ultrasound-Driven Lysis of Tumor-Resident Bacteria Awakens Innate Immunity for Systemic Cancer Therapy
Abstract Tumor-resident bacteria establish a profound immunosuppressive microenvironment that compromises cancer immunotherapy. While ablating these microbes holds therapeutic promise, broad-spectrum antibiotics can cause systemic dysbiosis, and the Gram-negative outer membrane can restrict the entry of conventional sonosensitizers, limiting the antibacterial efficacy of sonodynamic therapy (SDT). Here, we report an ultrasound-driven, bacteria-targeted immunotherapy utilizing polyarginine-functionalized peptide-sonosensitizer conjugates to achieve the in situ pulverization of the tumor Fusobacterium nucleatum (F. nucleatum), thereby eliciting potent innate antitumor immunity. The cationic conjugates electrostatically intercalate into Gram-negative bacterial membranes, inflicting a structural predisruption. Subsequent ultrasound irradiation synergizes localized sonochemical oxidation with mechanical shear forces to thoroughly shatter the bacteria. This targeted microbial fragmentation liberates massive quantities of pathogen-associated molecular patterns (PAMPs) that, unlike tumor-derived signals from conventional SDT, decisively reprogram macrophages toward an antitumor M1 phenotype to awaken innate immunity. Synchronized with tumor-specific antigens released via conjugate-induced immunogenic cell death, the liberated PAMPs synergistically amplify antigen presentation and optimally drive dendritic cell maturation. In a bacteria-colonized murine colorectal cancer model, this localized therapy markedly suppressed primary tumor growth and elicited both a pronounced abscopal effect against distant tumors and antitumor immune memory. By repurposing complicit bacteria into potent endogenous adjuvants, this ultrasound-driven strategy reverses bacteria-mediated immunosuppression, offering a transformative paradigm for treating microbiome-colonized solid tumors.
Authors
- Haoqi Zhu (ORCID: https://orcid.org/0000-0002-1269-7576)
- M. Wu (ORCID: https://orcid.org/0000-0003-2114-6343)
- Yi Cao (ORCID: https://orcid.org/0000-0003-1493-7868)
- Bin Xue (ORCID: https://orcid.org/0000-0002-0822-6501)
- Xiqun Jiang (ORCID: https://orcid.org/0000-0003-0483-0282)
- Zhen Cheng Xu (ORCID: https://orcid.org/0000-0003-1652-5496)
- Hanqing Qian (ORCID: https://orcid.org/0000-0002-7743-6019)
- Haoze Li
- Wenya Zhou
- Shaopeng Liu
- Rui Qu
- Siqi Li
- Yu Liu
Institutions
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Journal of the American Chemical Society
- Published
- 2026-10-29
- DOI
- https://doi.org/10.1021/jacs.6c14587
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- State Key Laboratory of Analytical Chemistry for Life Sciences